Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting
Cartesian Therapeutics, Inc. (RNAC)
Company Research
Source: GlobeNewswire
FREDERICK, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that safety and tolerability data from patients treated with Descartes-08 will be featured during a poster presentation at the upcoming 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 7-10, 2024 in San Diego. A copy of the abstract is available on the ASH website at www.hematology.org. Descartes-08, Cartesian’s lead mRNA cell therapy candidate, is an autologous mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T) product candidate targeting B-cell maturation antigen (BCMA). Details of the poster presentation are as follows: Publication Number: 2080Title: Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune DiseasesPresenter: Miloš Miljkovic, M.D., M.Sc., C
Show less
Read more
Impact Snapshot
Event Time:
RNAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNAC alerts
High impacting Cartesian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RNAC
News
- Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit [Yahoo! Finance]Yahoo! Finance
- Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease SummitGlobeNewswire
- Timothy Springer Bought 4.9% More Shares In Cartesian Therapeutics [Yahoo! Finance]Yahoo! Finance
- Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024 [Yahoo! Finance]Yahoo! Finance
- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) had its price target lowered by analysts at HC Wainwright from $45.00 to $41.00. They now have a "buy" rating on the stock.MarketBeat
RNAC
Earnings
- 5/8/24 - Miss
RNAC
Sec Filings
- 11/21/24 - Form 4
- 11/21/24 - Form 4
- 11/21/24 - Form 4
- RNAC's page on the SEC website